| Literature DB >> 31543912 |
Enas Fakhry Abdelhamed1, Eman Magdy Fawzy1, Said Mahmoud Ahmed2, Rabab Sayed Zalat3, Hayam Elsaid Rashed4.
Abstract
BACKGROUND: Cryptosporidium parvum is a dangerous intestinal pathogen due to its devastating effect on immunocompromised individuals. Considering low efficacy, high toxicity in addition to the development of resistance for the drugs used, this study aimed to find a new alternative treatment having the advantage of lower doses and minimal toxicity. We used a novel combination between artesunate loaded polymeric nanofiber (ALPN) and nanazoxide that had not been tried yet.Entities:
Keywords: Artesunate; Cryptosporidium; Oxidative stress; Polymeric nanofiber
Year: 2019 PMID: 31543912 PMCID: PMC6737357
Source DB: PubMed Journal: Iran J Parasitol ISSN: 1735-7020 Impact factor: 1.012
The mean number and the percentage reduction of Cryptosporidium oocyst shedding in immunocompromised mice treated with artesunate loaded polymeric nanofiber
| G I | 81.75 ± 8.82 (70–90) | ||
| GII | 73.3 ± 8.79 (39–80) | 42.5 | |
| GIII | 72.5 ± 8.75 (20–77) | 57.2 | |
| GIV | 4.5 ± 1.19 (3–6) | 94.4 | |
| GV | 75 ± 8.73 (55–80) | 16.5 |
P<0.001** highly significant difference
P<0.05 * significant difference
P1 means statistical difference between 5 groups
P2 means statistical difference between G I versus G II
P3 means statistical difference between G I versus G III
P4 means statistical difference between G I versus G IV
P5 means statistical difference between G I versus G V
The total antioxidant capacity in immunocompromised mice treated with artesunate loaded polymeric nanofiber
| Mean ± SD (Range) | ||||||
| Liver (Mm/g) | 2.08±0.09 (1.8–2.9) | 2.03 ± 0.08 (2.0–2.89) | 3.5±1.85 (3.0–3.9) | 10.15±1.15 (8.64–11.49) | 3.33± 2.07 (2.65–8.64) | |
| Intestine (Mm/g) | 5.78 ± 0.26 (5.12–6.56) | 6.12 ± 0.84 (5.42–7.57) | 6.33 ± 0.69 (6.12–8.98) | 22.4 ± 1.62 (20.6–24.7) | 6.22 ± 0.53 (5.79–8.0) | |
| Kidney (Mm/g) | 1.27± 0.18 (0.89–1.9) | 1.67± 0.38 (1.23–1.91) | 2.34± 1.16 (2.13–4.98) | 6.22± 1.65 (4.32–8.99) | 1.94± 0.90 (0.99–3.23) | |
| Serum (Mm/l) | 3.2 ± 0.29 (3.2–4.1) | 3.78 ± 0.60 (3.23–4.54) | 4.13 ± 0.67 (3.23–4.99) | 14.08 ± 0.97 (12.7–15.3) | 4.7± 0.23 (4.2–5.32) | |
P<0.001** highly significant difference
P<0.05 * significant difference
P1 means statistical difference between 5 groups
P2 means statistical difference between G I versus G II
P3 means statistical difference between G I versus G III
P4 means statistical difference between G I versus G IV
P5 means statistical difference between G I versus G V
Fig. 1:(a–b) Histopathological changes of intestinal epithelium in infected control immunocompromised group a-Intestinal epithelium showing high-grade dysplasia manifested by marked pleomorphism, absence of mucin, and frequent mitoses (arrows) (H&E ×400), b-showing presence of few parasites of Cryptosporidium at the brush border of epithelial cells of the villi (arrow) with infiltration of inflammatory cells (arrow) (H&E ×400)
Fig. 2:(c–d) Immunohistochemical changes of intestinal epithelium in infected control immunocompromised group compared to G: IVa (receiving combined treatment with nanazoxide and artesunate loaded nanofiber): c-Strong cytoplasmic expression of iNOS in the dysplastic intestinal epithelium infected by C.parvum (IHC ×400), d-Weak cytoplasmic expression of iNOS (IHC x400)
Fig. 3:Amplification plot showing results of stool samples by real-time PCR assay. Plots (g, h) have fluorescent values above threshold line “horizontal blue line” so considered positive samples but with different Ct values. Plots (a, b) were ACTB controls while the remaining plots were amplified standards. N were negative samples